Watson Abruptly Quits From Cold Spring Harbor Lab in Wake of Racist Remarks

[October 25, 2007]

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — James Watson this morning resigned as chancellor and board member of Cold Spring Harbor Laboratory, two weeks after comments he made that blacks are genetically inferior to whites sparked widespread public condemnation.

He disclosed his decision in a rambling e-mail six days after CSHL suspended him from his duties as chancellor as a result of his “racist” remarks.

“Closer now to 80 than 79, the passing on of my remaining vestiges of leadership is more than overdue,” Watson wrote. “The circumstances in which this transfer is occurring, however, are not those which I could ever have anticipated or desired.”

The lab this morning confirmed Watson’s intention to retire immediately, but did not refer to the circumstances surrounding the move.

“[Watson’s] legacy as a 1962 Nobel Prize laureate for describing the structure of DNA will continue to influence biomedical research for decades to come,” Eduardo Mestre, who is chairman of the board at CSHL, said in today’s statement from the lab. “The Board respects his decision to retire at this point in his career.”

In his letter, Watson discusses his history with CSHL and his Scottish ancestry and “moral values passed on to me by my father,” and said recent events have led him to focus “intensely” on those values.

He also wrote about the effects the Human Genome Project will have on healthcare, particularly mental diseases, and touched on his own family’s history with mental illness.

“Only after we understand [mental diseases] at the genetic level can we rationally seek out appropriate therapies for such illnesses as schizophrenia and bipolar disease,” Watson wrote. “For the children of my sister and me, this moment can not come a moment too soon.

“Hell does not come close to describing the impact of psychotic disorders on human life,” he added, concluding that he has “been much blessed.”

The letter did not mention directly the remarks that ultimately led to his decision to retire. Rather, he wrote that “this week’s events focus me ever more intensely on the moral values passed on to me by my father, whose Watson surname marks his long ago Scots-Irish Appalachian heritage; and by my mother, whose father, Lauchlin Mitchell, came from Glasgow and whose mother, Lizzie Gleason, had parents from Tipperary.

“To my great advantage, their lives were guided by a faith in reason; an honest application of its messages; and for social justice, especially the need for those on top to help care for the less fortunate,” Watson wrote.

In CSHL’s statement, CSHL Director Bruce Stillman said Watson’s “legacy will not only include CSHL and the double helix, but his pioneering efforts that led to the sequencing of the human genome and his innovations in science writing and education.”

La génétique rebat les cartes de l’industrie pharmaceutique

LE MONDE ECONOMIE | 22.10.07 | 11h20  •  Mis à jour le 22.10.07 | 11h21

L’utilisation de tests génétiques dans le cadre de la politique d’immigration pourrait avoir des conséquences inattendues. Au-delà de la polémique politique, juridique et morale, le débat contribue peut-être à familiariser la population avec un outil dont on commence à peine à percevoir les effets de régulation sociale. Un pur bénéfice pour les entreprises qui conçoivent et fabriquent les équipements, kits et produits chimiques destinés à analyser les fluides et les tissus issus du corps humain.

La nécessité de comprimer les dépenses de santé, en ciblant mieux les prescriptions et en tentant d’associer un médicament à des catégories précises de patients, donne en effet une place croissante au diagnostic in vitro (DIV) : d’ores et déjà les résultats de ce type d’examen influent sur 70 % des décisions médicales. Le DIV a représenté un marché mondial de plus de 30 milliards d’euros en 2006, selon les chiffres fournis par l’Association des fabricants de diagnostic européens (Edma).

Les diagnostics in vitro sont restés longtemps confinés aux laboratoires. En Europe, ses utilisateurs demeurent avant tout les patients, les médecins, les autorités de santé, et les organismes d’assurance-maladie publics ou privés. Aux Etats-Unis aussi, l’essentiel du marché est réalisé entre acteurs du système de soins. Mais d’autres utilisateurs - particuliers, magasins, écoles, entreprises… - ont fait leur apparition. Un nombre croissant de patients se montrent intéressés par l’achat de tests en vente libre, dont chacun est seul à connaître le résultat (tests de grossesse, par exemple). Les assureurs encouragent également les patients américains à recourir spontanément à ces “autotests” dans la mesure où cela les dispense de rembourser une facture issue des centres de soins spécialisés. Enfin, la montée en puissance de maladies chroniques comme le diabète donne un coup de fouet aux outils personnalisés de mesure du taux de glucose. Quand on sait que l’Organisation mondiale de la santé prévoit 300 millions de diabétiques à l’horizon 2025, on mesure l’importance du chiffre d’affaires futur…

“DE NOUVELLES PERCÉES”

L’essentiel du marché du diagnostic in vitro utilise encore les techniques traditionnelles d’analyse : hématologie, immunologie, biochimie, microbiologie, etc. Mais deux domaines tirent tout le secteur : les tests de glucose (12 %) dont on vient de voir l’importance, et le diagnostic moléculaire.

Les tests moléculaires (ou génétiques) qui représentent déjà 20 % du marché mondial ont pour but d’étudier et mesurer les variations et mutations du matériel génétique humain, quand le médecin soupçonne qu’il est à l’origine de maladies ou de désordres physiologiques. “Ce segment de marché est en hausse rapide et croît de 12 % à 15 % par an, alors que le reste du marché diagnostic ne croît que de 2 % à peine par an. La biologie moléculaire a ouvert la voie à de nouvelles percées thérapeutiques contre des maladies mortelles comme le cancer et certaines maladies génétiques”, indique Alain Gilbert, directeur associé de la société de conseil Bionest Partners.

Outre la médecine de pointe (prédispositions aux cancers, aide à la transplantation d’organes, etc.), le diagnostic moléculaire trouve des applications dans la médecine légale, la lutte contre le bioterrorisme, l’alimentation et la santé publique. Surtout, l’industrie pharmaceutique en a fait un outil de développement de nouveaux médicaments mieux ciblés.

Parmi les technologies qui dynamisent ce secteur, on peut citer les puces à ADN (mais aussi à nucléotides et à protéines) dont les ventes ont dépassé le milliard de dollars en 2006. Ces instruments, qui tiennent dans la paume de la main, permettent d’effectuer un nombre toujours plus important de tests en simultané et jouent un rôle-clé dans de nouvelles disciplines comme la protéomique (sciences de protéines), et dans les applications de la génomique à l’analyse des pathologies, autrement dit la pharmacogénomique.

Le marché de la pharmacogénomique est considéré comme le plus prometteur par l’industrie pharmaceutique par les avancées qu’il ouvre dans la médecine personnalisée. A l’heure actuelle, la plupart des médicaments sont vendus à des populations globales de malades sans possibilité de les cibler avec précision. Les tests génétiques devraient, à l’avenir, permettre de déterminer les sous-groupes de patients éligibles à tel ou tel médicament avec des chances de guérison proches de 100 %. Ces produits se comptent encore sur les doigts d’une main, mais les laboratoires pharmaceutiques les plus en pointe sur le sujet obtiendront des autorités sanitaires les meilleurs prix au moment des autorisations de mise sur le marché. C’est le marché du médicament dans son ensemble qui attend ainsi de l’usage croissant des tests génétiques les plus amples résultats.

Yves Mamou
Article paru dans l’édition du 23.10.07

CSHL Suspends James Watson Over ‘Racist’ Comments; Says It ‘Disagrees’ With His Remarks

[October 19, 2007]

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) — James Watson has been suspended as Chancellor of Cold Spring Harbor Laboratory after he was quoted this week making racist comments against people of African ancestry.

Yesterday evening, the Cold Spring Harbor Laboratory Board of Trustees “decided to suspend the administrative responsibilities” of Watson “pending further deliberation by the Board.”

The board said it took the step after it made a statement yesterday “disagreeing” with the comments “attributed to Watson” in the Oct. 14 edition of The Sunday Times.

In those comments, Watson opined that people of African ancestry may be genetically less intelligent than other races.

“All our social policies are based on the fact that their intelligence is the same as ours, whereas all the testing says not really,” the paper reported. “People who have to deal with black employees find this is not true.”

He went on to say that “there is no firm reason to anticipate that the intellectual capacities of peoples geographically separated in their evolution should prove to have evolved identically,” according to the paper.

“Our wanting to reserve equal powers of reason as some universal heritage of humanity will not be enough to make it so,” the paper quoted Watson as saying.

In an apology released today, Watson said: “To all those who have drawn the inference from my words that Africa, as a continent, is genetically inferior, I can only apologize unreservedly.

“That is not what I meant. More importantly, there is no scientific basis for such a belief,” he said.

According to the Times, which tape-recorded its interview with the Nobel laureate, Watson also suggested that he was misquoted, saying, “I cannot understand how I could have said what I am quoted as having said. I can certainly understand why people reading those words have reacted in the ways they have.”

Calls to CSHL for elaboration on Watson’s status and duties as chancellor were not immediately returned.

Fury at DNA pioneer’s theory: Africans are less intelligent than Westerners

Celebrated scientist attacked for race comments: “All our social policies are based on the fact that their intelligence is the same as ours - whereas all the testing says not really”

By Cahal Milmo

Published: 17 October 2007

One of the world’s most eminent scientists was embroiled in an extraordinary row last night after he claimed that black people were less intelligent than white people and the idea that “equal powers of reason” were shared across racial groups was a delusion.

James Watson, a Nobel Prize winner for his part in the unravelling of DNA who now runs one of America’s leading scientific research institutions, drew widespread condemnation for comments he made ahead of his arrival in Britain today for a speaking tour at venues including the Science Museum in London.

The 79-year-old geneticist reopened the explosive debate about race and science in a newspaper interview in which he said Western policies towards African countries were wrongly based on an assumption that black people were as clever as their white counterparts when “testing” suggested the contrary. He claimed genes responsible for creating differences in human intelligence could be found within a decade.

The newly formed Equality and Human Rights Commission, successor to the Commission for Racial Equality, said it was studying Dr Watson’s remarks ” in full”. Dr Watson told The Sunday Times that he was “inherently gloomy about the prospect of Africa” because “all our social policies are based on the fact that their intelligence is the same as ours – whereas all the testing says not really”. He said there was a natural desire that all human beings should be equal but “people who have to deal with black employees find this not true”.

His views are also reflected in a book published next week, in which he writes: “There is no firm reason to anticipate that the intellectual capacities of peoples geographically separated in their evolution should prove to have evolved identically. Our wanting to reserve equal powers of reason as some universal heritage of humanity will not be enough to make it so.”

The furore echoes the controversy created in the 1990s by The Bell Curve, a book co-authored by the American political scientist Charles Murray, which suggested differences in IQ were genetic and discussed the implications of a racial divide in intelligence. The work was heavily criticised across the world, in particular by leading scientists who described it as a work of ” scientific racism”.

Dr Watson arrives in Britain today for a speaking tour to publicise his latest book, Avoid Boring People: Lessons from a Life in Science. Among his first engagements is a speech to an audience at the Science Museum organised by the Dana Centre, which held a discussion last night on the history of scientific racism.

Critics of Dr Watson said there should be a robust response to his views across the spheres of politics and science. Keith Vaz, the Labour chairman of the Home Affairs Select Committee, said: “It is sad to see a scientist of such achievement making such baseless, unscientific and extremely offensive comments. I am sure the scientific community will roundly reject what appear to be Dr Watson’s personal prejudices.

“These comments serve as a reminder of the attitudes which can still exists at the highest professional levels.”

The American scientist earned a place in the history of great scientific breakthroughs of the 20th century when he worked at the University of Cambridge in the 1950s and 1960s and formed part of the team which discovered the structure of DNA. He shared the 1962 Nobel Prize for medicine with his British colleague Francis Crick and New Zealand-born Maurice Wilkins.

But despite serving for 50 years as a director of the Cold Spring Harbor Laboratory on Long Island, considered a world leader in research into cancer and genetics, Dr Watson has frequently courted controversy with some of his views on politics, sexuality and race. The respected journal Science wrote in 1990: “To many in the scientific community, Watson has long been something of a wild man, and his colleagues tend to hold their collective breath whenever he veers from the script.”

In 1997, he told a British newspaper that a woman should have the right to abort her unborn child if tests could determine it would be homosexual. He later insisted he was talking about a “hypothetical” choice which could never be applied. He has also suggested a link between skin colour and sex drive, positing the theory that black people have higher libidos, and argued in favour of genetic screening and engineering on the basis that ” stupidity” could one day be cured. He has claimed that beauty could be genetically manufactured, saying: “People say it would be terrible if we made all girls pretty. I think it would great.”

The Cold Spring Harbor Laboratory said yesterday that Dr Watson could not be contacted to comment on his remarks.

Steven Rose, a professor of biological sciences at the Open University and a founder member of the Society for Social Responsibility in Science, said: ” This is Watson at his most scandalous. He has said similar things about women before but I have never heard him get into this racist terrain. If he knew the literature in the subject he would know he was out of his depth scientifically, quite apart from socially and politically.”

Anti-racism campaigners called for Dr Watson’s remarks to be looked at in the context of racial hatred laws. A spokesman for the 1990 Trust, a black human rights group, said: “It is astonishing that a man of such distinction should make comments that seem to perpetuate racism in this way. It amounts to fuelling bigotry and we would like it to be looked at for grounds of legal complaint.”

 

http://news.independent.co.uk/sci_tech/article3067222.ece

Purdue professor shares Nobel Peace Prize with Al Gore

October 16, 2007

Purdue professor shares Nobel Peace Prize with Al Gore

WEST LAFAYETTE, Ind. - A Purdue University professor is among the co-recipients of the 2007 Nobel Peace Prize, alongside former Vice President Al Gore, “for their efforts to build up and disseminate greater knowledge about manmade climate change and to lay the foundations for the measures that are needed to counteract such change.”

Kevin Gurney, associate director of Purdue’s Climate Change Research Center, will share in the award as one of the 2,500 international climate scientists who played various roles in the Intergovernmental Panel on Climate Change, which won the Nobel Prize with Gore.

 

The Nobel committee cited the IPCC’s two decades of scientific reports, saying they have “created an ever-broader informed consensus about the connection between human activities and global warming.”

Gurney is a member of IPCC, which commissions assessments of global climate change from hundreds of experts in the field. The fourth assessment report, published this year, was based on computer modeling of global climate. Gurney, who also is an assistant professor of earth and atmospheric sciences, contributed research results on linkages between climate change and carbon cycling to the most recent IPCC assessment.

The Nobel Prizes will be awarded during ceremonies on Dec. 10 in Stockholm and Oslo.

 

Writer: Elizabeth Gardner, (765) 494-2081, ekgardner@purdue.edu

 

Purdue News Service: (765) 494-2096; purduenews@purdue.edu

Just released - Peter Singer

Stem Cell Research - The Ethical Issues

Edited by: Lori Gruen (Wesleyan University), Laura Grabel (Wesleyan University) and Peter Singer (Princeton University)

Description

  • In this timely collection, some of the world’s leading ethicists grapple with the variety of issues posed by human embryonic stem cell research.
  • Investigates the moral status of the embryo including the creation of chimeras and paying for gametes (eggs and sperm) and embryos for research purposes
  • Provides a thorough evaluation of the ethics and politics of regulating hESC research, and the privacy, confidentiality, and informed consent in the conduct of research and clinical investigations
  • Essential reading for scientists, philosophers, policy makers, and all who are interested in the ethical conduct of science
  • Contributors include David DeGrazia, Lori Gruen, Elizabeth Harman, John Harris, Jeff McMahan, Don Marquis and Peter Singer

Table of Contents

Notes on Contributors
1. Introduction: Laura Grabel and Lori Gruen
2. The Ambiguity of the Embryo: Ethical Inconsistency in the Human Embryonic Stem Cell Debate: Katrien Devolder and John Harri
3. Killing Embryos for Stem Cell Research: Jeff McMahan
4. The Moral-Principle Objection to Human Embryonic Stem Cell Research: Don Marquis
5. How is the Ethics of Stem Cell Research Different from the Ethics of Abortion?: Elizabeth Harman
6. Respecting Human Embryos within Stem Cell Research: Seeking Harmony: Bertha Alvarez Manninen
7. Rescuing Human Embryonic Stem Cell Research: The Possibility of Embryo Reconstitution after Stem Cell Derivation: Katrien Devolder and Christopher M. Ward
8. The Moral Status of Stem Cells: Agata Sagan and Peter Singer
9. Oocytes for Sale?: Lori Gruen
10. Human-Animal Chimeras: Human Dignity, Moral Status, and Species Prejudice: David Degrazia
11. Why No Compromise is Possible: Torbjörn Tännsjö

 

http://www.blackwellpublishing.com/book.asp?ref=9781405160629&site=1

 

The Bioethics Reader

Edited by: RUTH CHADWICK, HELGA KUHSE (Monash University), WILLEM A. LANDMAN (Ethics Institute of South Africa (EthicSA) and University of Stellenbosch), UDO SCHÜKLENK (Queen’s University, Kingston, Ontario) and PETER SINGER (Princeton University and The University of Melbourne)

Description

A collection celebrating some of the best essays from the Blackwell journals, Bioethics and Developing World Bioethics.

  •  Contributors include Helga Kuhse, Michael Selgelid and Baroness Mary Warnock, former Chair of the British Government’s Committee of Inquiry into Human Fertilization and Embryology’s.
  • Traces some of the most important concerns of the 1980s, such as the ethics of euthanasia, reproductive technologies, the allocation of scarce medical resources, surrogate motherhood, through to a range of new issues debated today, particularly in the field of genetics.
  • Includes contributions that are still as hotly debated today as they were 20 years ago and serves as a salutary reminder that free and open discussion is vital to the health of the discipline itself.
  • Includes eight sections comprising some of the journals’ best publications in methodological issues, the health care professional-patient relationship, public health ethics, research ethics, genetics, as well as beginning- and end-of-life issues.
  • Will serve the academic bioethicists as well as students of bioethics as an excellent source book.

Table of Contents

Introduction: Ruth Chadwick, Helga Kuhse, Willem Landman, Udo Schüklenk, and Peter Singer
Part I: Doing Bioethics:
1. A Report from America: When Philosophers Shoot from the Hip: James Rachels
2. Rethinking Medical Ethics: A View from Below: Paul Farmer and Nicole Gastineau Campos
3. What Can the Social Sciences Contribute to the Study of Ethics? Theoretical, Empirical and Substantive Considerations: Erica Hajmes
4. In Defense of Posthuman Dignity: Nick Bostrom

Part II: Healthcare Professional-Patient Relationship:
5. Patients’ Responsibilities in Medical Ethics: Heather Draper and Tom Sorell
6. Clinical Ethics and Nursing: ‘Yes’ to Caring, But ‘No’ to a Female Ethics of Care: Helga Kuhse
7. Background Briefing Psychiatric Ethics: Jennifer Radden
8. Female Genital Mutilation and Cosmetic Surgery: Regulating Non-Therapeutic Body Modification: Sally Sheldon and Stephen Wilkinson

Part III: Just Health Care:
9. Patents and Access to Drugs in Developing Countries: An Ethical Analysis: Sigrid Sterckx
10. Justice and Equal Opportunities in Health Care: John Harris
11. Constraints and Heroes: Carl Elliott
Part IV: Public Health Ethics:
12. The Genesis of Public Health Ethics: Ronald Bayer and Amy L. Fairchild
13. Ethics and Infectious Disease: Michael J. Selgelid
14. Vaccination and the Prevention Problem: Angus Dawson


Part V: Research Ethics:
15. Background Briefing: International Research Ethics: Udo Schüklenk and Richard Ashcroft
16. Equipoise and International Human-Subjects Research: Alex John London
17. Symposium: Drugs for the Developing World,
Developing Drugs for the Developing World: An Economic, Legal, Moral, and Political Dilemma: David B. Resnik
18. Some Questions about the Moral Responsibilities of Drug Companies in Developing Countries: Dan W. Brock
19. Social Responsibility and Global Pharmaceutical Companies: Norman Daniels
Part VI: Genetics:
20. Do Human Cells Have Rights?: Mary Warnock
21. Going to the Roots of the Stem Cell Controversy: Søren Holm
22. Designing Babies: Morally Permissible Ways to Modify the Human Genome: Nicholas Agar
23. The Non-Identity Problem and Genetic Harms - the Case of Wrongful Handicaps: Dan W. Brock
24. Coding and Consent: Moral Challenges of the Database Project in Iceland: Vilhjálmur Árnason
Part VII: Beginning of Life Issues:
25. Is It Good to Make Happy People?: Stuart Rachels
26. Genes, Embryos, and Future People: Walter Glannon
27. Procreative Beneficence: Why We Should Select the Best Children: Julian Savulescu
28. The Problem of Abortion: Essentially Contested Concepts and Moral Autonomy: Susanne Gibson
29. Law and Bioethics, The Injustice of Unsafe Motherhood: Rebecca J. Cook and Bernard M. Dickens
30. The Limits of Conscientious Objection to Abortion in the Developing World: Louis-Jacques van Bogaert
31. Surrogate Mothering: Exploitation or Empowerment?: Laura M. Purdy
Part VIII: End of Life:
32. The Metaphysics of Brain Death: Jeff McMahan
33. Advance Directives, Autonomy and Unintended Death: Jim Stone
34. End of Life Care in HIV-Infected Children Who Died in Hospital: Lesley D. Henley
Index

GMO - debate with Jacques Attali

Les OGM
A l’avenir les prix de l’alimentation vont monter parce qu’on ne produira pas assez sans OGM. Qu’est ce que les OGM ? Pourquoi tous les pays du monde les utilisent-ils aujourd’hui à l’exception de la France ? Ils sont très controversés : quels en sont les dangers ? Que se passera t il pour les pays qui ne les utiliseront pas ? La technologie alimentaire pourrait-elle servir les intérêts de l’humanité et non servir uniquement les intérêts des grands groupes industriels ?

 http://publicsenat.fr/archives/emission.asp?emission=38

Upcoming events

October 18, 2007
American Society for Bioethics and Humanities Annual Meeting

www.asbh.org

Description

The meeting will feature an array of preconference workshops, interdisciplinary panels, workshops, paper and poster presentations organized around the theme Connecting & Collaborating. The meeting brochure will be available this summer.

Location
Washington, DC

Contact Information
Amy Claver
aclaver@connect2amc.com
847-375-4745

 

November 1, 2007
3rd International Conference on Science and Ethics of ART

Description
At our “3rd International Conference on Science and Ethics of Assisted Human Reproduction and Stem Cell Research” we will discuss the medical, moral, legal and social implications of new reproductive technologies and embryonic stem cell research. Among the many topics to be addressed are tissue engineering, therapeutic cloning, emergency contraception, egg donation, preimplantation genetic diagnosis, the welfare of children, conflicts between science and religion, and public policy making in secular societies. Among the speakers are Robert G. Edwards, Jonathan Glover, Laura Purdy, John Harris, Susan Golombok and Timothy F. Murphy.

Location
Berlin,

Contact Information
Dr. Edgar Dahl
presse@repromedizin.de
+49 641 68 68 42

First Hybrid Train - “Bibi” France

J.B. (lefigaro.fr) Avec AFP

Publié le 09 octobre 2007

Actualisé le 09 octobre 2007 : 15h18
Crédits photo : François Nascimbeni/AFP

Le premier train hybride au monde a été inauguré mardi en France lors d’un voyage entre Paris et Troyes. Fabriqué par le canadien Bombardier dans l’usine française de Crespin (Nord), ce train régional “est en fait deux fois hybride, ce qui lui vaut le surnom de “bibi”: il est “bi-mode”, c’est-à-dire qu’il dispose à la fois d’un moteur diesel et d’une propulsion électrique. Il est en mesure de passer d’un mode à l’autre sans s’arrêter, une première mondiale selon Bombardier. Mais il est aussi “bi-courant”: il peut recevoir une tension de 1.500 volts ou de 25.000 volts grâce à un transformateur situé sur le toit. Cet ensemble d’innovations en fait le premier train à fonctionner de façon totalement hybride dans le monde, selon Bombardier. Les voyageurs n’ont donc pas à changer de train ou à attendre un changement de locomotive lorsque le convoi passe d’un type de voie à un autre.

20% de CO2 en moins
“Hybride bibi” permet aussi de rejeter moins de gaz à effet de serre dans l’atmosphère. En parcourant le trajet depuis Paris avec ce train, “nous avons économisé 20% de CO2 par rapport à un train diesel et 60% par rapport à une voiture”, a-t-il aussi affirmé. Selon lui, ce train “permet de redorer l’image du train régional en France”.
L’achat de huit rames de ce type a coûté 40 millions d’euros à la région Champagne-Ardenne. Une rame hybride bi-mode, bi-courant coûte entre 10 et 20% de plus qu’une rame Bombardier classique, a-t-on précisé chez Bombardier.
Dix régions françaises ont déjà commandé environ 144 “bibi”: Champagne-Ardenne, Rhône-Alpes, Poitou-Charentes, Ile-de-France, Bretagne, Haute-Normandie, Bourgogne, Picardie, Nord-Pas-de-Calais et Alsace.

L’inauguration de ce nouveau train régional hybride a été l’occasion pour le maire de Troyes, François Baroin, et le président de la région Champagne-Ardenne Jean-Paul Bachy, de critiquer la SNCF et Réseau ferré de France, propriétaire du réseau, à propos des lenteurs de modernisation que connaît selon eux la ligne Paris-Troyes, en attente d’électrification. Anne-Marie Idrac, présidente de la SNCF les a assurés de sa volonté de faire avancer le dossier.

Our Commitment to the Environment (Morgan Stanley)

August 28, 2007

Office of the Environment

Morgan Stanley recognizes the critical importance of a healthy environment to our global society, our economy, our business and our people. We also realize the potential impacts that today’s environmental challenges will have if left unaddressed. Given our position as one of the world’s leading financial services firms and our ongoing commitment to good corporate citizenship, we have a responsibility to manage and leverage our resources in a way that promotes a healthy and sustainable environment.

As such, we are committed to considering environmental issues in all aspects of our business, including how we evaluate companies, transactions and risk; how we collaborate with and educate our clients, financing partners and employees; how we conduct our own operations; and how we promote and develop new market opportunities.

We believe that our approach to environmental issues helps us pursue our principal focus of creating long-term value for our shareholders and serving the long-term interests of our clients.

This Policy Statement, which updates the Environmental Policy Statement first implemented in 2002, reflects Morgan Stanley’s ongoing commitment to the environment and highlights the ways our business decisions and policies address the opportunities and challenges raised by today’s most significant environmental matters.
View Morgan Stanley’s Environmental Policy Statement.

http://www.morganstanley.com/views/perspectives/articles/5430.html

Next Page »